Compounds with acne-treating effects and their applications in skincare products

Abstract

This application provides a compound and skincare product with acne-treating efficacy. The compound with acne-treating efficacy includes a bioactive surfactant. This compound uses a non-irritating bioactive surfactant and natural, green plant extracts, exhibiting good acne-treating efficacy. It can quickly and effectively reduce excess sebum, reduce inflammation and swelling, while also being safe and non-irritating. Furthermore, this compound has good compatibility and can be widely used in various acne-reducing and anti-inflammatory products, such as liquids and creams.

Description

Technical Field

[0001] This application relates to the field of cosmetic technology, and in particular to a compound with acne-treating effects, its application, and skin care products. Background Technology

[0002] Acne is a chronic inflammatory skin disease of the pilosebaceous unit, primarily affecting adolescents, but symptoms can occur in other age groups as well. The main cause of acne is the conversion of testosterone (androgens) in sebaceous gland cells to the more potent dihydrotestosterone (DHT) by 5α-reductase, leading to abnormally increased sebum secretion. This is especially true after puberty when increased androgen levels further exacerbate sebum production, creating ideal conditions for the proliferation of Gram-positive anaerobic bacteria, such as Propionibacterium acnes. Simultaneously, the skin may be infected with Gram-positive aerobic bacteria such as Staphylococcus epidermidis and Staphylococcus aureus. Propionibacterium acnes is the dominant bacteria on the skin, mainly distributed in hair follicles and sebaceous glands. It produces enzymes that break down skin tissue and immunogenic proteins. Additionally, a small polypeptide it produces attracts phagocytes to the bacterial colony, releasing enzymes and various inflammatory mediators, leading to the breakdown of sebum into free acids and resulting in inflammatory reactions such as redness, swelling, and pain.

[0003] Currently, acne is generally treated with antibiotics such as erythromycin, which may cause other side effects. Summary of the Invention

[0004] Based on this, this application provides a compound and skin care product with acne-treating effects to effectively treat acne while reducing side effects.

[0005] The first aspect of this application provides a compound having therapeutic effects on acne, said compound comprising a bioactive surfactant.

[0006] In some embodiments, the bioactive surfactant includes one or more of lipopeptide bioactive surfactants, glycolipid bioactive surfactants, and phospholipid bioactive surfactants.

[0007] In some embodiments, the compound further includes plant extracts, including one or more of the following: Platycladus orientalis leaf extract, Salvia miltiorrhiza extract, Coptis chinensis extract, Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract.

[0008] In some embodiments, the plant extract includes one or more of Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract.

[0009] In some embodiments, the bioactive surfactant includes one or more of the following features (1)-(3):

[0010] (1) The lipopeptide biosurfactant includes one or more of the following: subtilisin sodium lipopeptide, iturinin, and lichenin;

[0011] (2) The glycolipid biosurfactants include one or more of sophorolipids, rhamnolipids, and trehalolipids;

[0012] (3) The phospholipid biosurfactants include one or more of lecithin, inositol phospholipids, and serine phospholipids.

[0013] In some embodiments, the compound comprises, by weight parts:

[0014] 2-30 parts of lipopeptide biosurfactants, 1-20 parts of glycolipid biosurfactants, 2-20 parts of phospholipid biosurfactants, 0.6-8 parts of Paris polyphylla extract, 1.2-10 parts of Sapindus mukorossi extract, 1.5-10 parts of Portulaca oleracea extract, 3-10 parts of nicotinamide, 2-5 parts of butylene glycol, and 0.14-1.34 parts of p-hydroxyacetophenone.

[0015] In some embodiments, the compound comprises, by weight parts:

[0016] 5-15 parts of lipopeptide biosurfactants, 2-8 parts of glycolipid biosurfactants, 3-7 parts of phospholipid biosurfactants, 2-6 parts of Paris polyphylla extract, 2-6 parts of Sapindus mukorossi extract, 2-6 parts of Portulaca oleracea extract, 5-8 parts of nicotinamide, 3-5 parts of butylene glycol, and 0.173-0.75 parts of p-hydroxyacetophenone.

[0017] In some embodiments, the compound comprises, by weight parts:

[0018] 10 parts of lipopeptide biosurfactants, 6 parts of glycolipid biosurfactants, 6 parts of phospholipid biosurfactants, 2 parts of Paris polyphylla extract, 2 parts of Sapindus mukorossi extract, 2 parts of Portulaca oleracea extract, 5 parts of nicotinamide, 3 parts of butylene glycol and 0.14 parts of p-hydroxyacetophenone.

[0019] In some embodiments, the compound further includes sodium hydroxide;

[0020] Optionally, the amount of sodium hydroxide used is such that the pH of the compound is 6.8-7.5.

[0021] In some embodiments, the compound further includes water;

[0022] Optionally, the amount of water used is such that the total weight of the compound reaches 100 parts by weight.

[0023] The second aspect of this application provides the use of the compound of the first aspect of this application in the preparation of one or more skin care cosmetics, detergent cosmetics, makeup products and shampoo and conditioner products.

[0024] A third aspect of this application provides a skin care product comprising a compound of the first aspect of this application that has acne-treating effects.

[0025] In some embodiments, the skincare product comprises, by weight parts:

[0026] 0.1 to 5 parts of the compound, 0.2 to 0.8 parts of an antioxidant, 2 to 8 parts of an emulsifier, 10 to 20 parts of a skin emulsifier, 8 to 20 parts of a moisturizer, and 0.2 to 2 parts of a preservative.

[0027] In some embodiments, the skincare product comprises, by weight parts:

[0028] The compound contains 3-5 parts of the compound, 0.4-0.6 parts of an antioxidant, 3-5 parts of an emulsifier, 14-18 parts of a skin emulsifier, 8-12 parts of a moisturizer, and 0.4-1 part of a preservative.

[0029] In some embodiments, the skin care product includes at least one of the following features (1)-(5):

[0030] (1) The emulsifier includes one or more of the following: hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, cetearyl glucoside and cetearyl alcohol, eicosyl docosyl alcohol and eicosyl glucoside;

[0031] (2) The emollients include one or more of isopropyl palmitate, isononyl isononyl isononyl carbonate and dioctyl carbonate;

[0032] (3) The moisturizer includes one or more of isohexadecane, butanediol and glyceryl glucoside;

[0033] (4) The preservatives include one or more of p-hydroxyacetophenone, octanoyl hydroxamic acid and phenoxyethanol;

[0034] (5) The antioxidants include one or more of tocopheryl acetate, green tea extract and sodium sulfite.

[0035] In some embodiments, the skin care product is an emulsified skin cream.

[0036] The aforementioned compound and skincare products with acne-treating effects utilize non-irritating bioactive surfactants and natural, green plant extracts. They exhibit excellent acne-treating efficacy, effectively reducing excess sebum and inflammation while remaining safe and non-irritating. Furthermore, this compound has good compatibility and can be widely used in various acne-reducing and anti-inflammatory products, including liquids and creams. Detailed Implementation

[0037] To facilitate understanding of this application, a more complete description of the application will be provided below with reference to embodiments. Preferred embodiments of the application are given below. However, the application can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of this application.

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0039] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.

[0040] In this application, numerical ranges are referred to as continuous unless otherwise specified, and include the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0041] This document only specifically discloses some numerical ranges. However, any lower limit can be combined with any upper limit to form an unspecified range; and any lower limit can be combined with other lower limits to form an unspecified range, just as any upper limit can be combined with any other upper limit to form an unspecified range. Furthermore, each individually disclosed point or single value can itself serve as a lower or upper limit and be combined with any other point or single value or with other lower or upper limits to form an unspecified range.

[0042] Unless otherwise specified, the temperature parameters in this application may be either constant temperature processing or processing within a certain temperature range. The constant temperature processing allows for temperature fluctuations within the precision range controlled by the instrument.

[0043] In the description of the invention, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0044] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions. Unless otherwise specified, all technical features and optional technical features of this application can be combined to form new technical solutions.

[0045] Unless otherwise specified, all steps of this application may be performed sequentially or randomly, but sequentially is preferred.

[0046] In related technologies, acne is generally treated with antibiotics such as erythromycin, which may cause drug resistance or other side effects.

[0047] Based on the above problems, this application uses a compound containing bioactive surfactants and plant extracts to treat acne. Bioactive surfactants generally have antibacterial, anti-inflammatory, and antioxidant effects. For example, lipopeptide bioactive surfactants can inhibit the growth of Propionibacterium acnes; glycolipid surfactants can regulate the dilation of skin capillaries to treat rosacea and treat allergies, and have a certain inhibitory effect on Staphylococcus aureus; phospholipid bioactive surfactants have antioxidant and anti-aging effects, enhance immunity and inhibit inflammation. At the same time, combined with plant extracts that have antibacterial, anti-inflammatory and soothing effects, it effectively solves acne problems such as excessive sebum, skin redness and swelling, and allergic inflammation.

[0048] The first aspect of this application provides a compound having therapeutic effects on acne, the compound comprising a bioactive surfactant.

[0049] In some embodiments, the biosurfactant includes one or more of lipopeptide biosurfactants, glycolipid biosurfactants, and phospholipid biosurfactants.

[0050] Lipopeptides are a class of amphoteric substances composed of hydrophilic cyclic oligopeptides and hydrophobic fatty acid chains. Multiple amino acids form the hydrophilic group, while the aliphatic hydrocarbon chain forms the lipophilic group. Based on the types and numbers of amino acids and the cyclic groups in the peptide ring, Bacillus lipopeptides can be classified into surfactants, fenbufen (also known as fenbufen), and iturofurin, among others. Typically, surfactants consist of a 12-17 carbon atom β-hydroxy fatty acid and 7 α-amino acids. Fenbufen consists of a 14-17 carbon atom β-hydroxy fatty acid and 10 amino acids. Iturofurin consists of a 14-17 carbon atom β-amino fatty acid and a heptapeptide peptide chain. Lipopeptides have extremely low CMC values, ranging from 100 to 300 mg / L; they can reduce the surface tension of water from 72 mN / m to as low as 28 mN / m. They still exhibit strong activity at extremely low concentrations (≤30 mg / L). Lipopeptides can inhibit the catalytic conversion of male hormones by 5α-reductase to a certain extent and have low irritant properties.

[0051] Glycolipid surfactants are complexes composed of sugars and long-chain fatty acids or hydroxylated fatty acids. The sugars can be repeating units of monosaccharides, disaccharides, trisaccharides, or tetrasaccharides, such as glucose, glucuronic acid, rhamnose, galactose, mannose, and galactose sulfate. Common examples of glycolipid surfactants include trehalose, rhamnose, sophorolipids, and mannose-erythritol esters. Glycolipid biosurfactants possess properties that promote cell penetration, treat rosacea, treat allergies, and have antibacterial and anti-aging effects.

[0052] Phospholipid biosurfactants are lipid compounds containing phosphate groups. Phospholipid molecules contain both hydrophilic phosphate groups and hydrophobic fatty acid ester groups, significantly reducing the interfacial tension between water and oil. Phospholipid biosurfactants include, but are not limited to, lecithin, inositol phospholipids, and serine phospholipids. Lecithin is mainly composed of a glycerol backbone, one phosphate group, two fatty acid groups (R1 and R2), and head groups of different polarities. The fatty acids typically have an even number of carbon atoms, such as 16, 18, or 20, and often contain unsaturated fatty acids. Phospholipid biosurfactants possess antioxidant and anti-aging properties, activate cells, enhance immunity, and suppress inflammation.

[0053] In some embodiments, the compound further includes plant extracts, including one or more of the following: Platycladus orientalis leaf extract, Salvia miltiorrhiza extract, Coptis chinensis extract, Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract.

[0054] In some alternative implementations, the plant extract includes one or more of Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract.

[0055] Sapindus mukorossi possesses significant antibacterial and anti-inflammatory pharmacological effects, along with excellent surface activity. Its extract exhibits good inhibitory activity against Propionibacterium acnes; a concentration of 2.00 mg / mL of the pericarp extract can achieve a 100% inhibition rate against Propionibacterium acnes without inducing drug resistance, making it one of the effective plant extracts for treating acne. The extraction process for Sapindus mukorossi extract is as follows: Place the Sapindus mukorossi pericarp in an electric heating drying oven and dry at 80℃-100℃. Grind it into powder using a pulverizer. Weigh the Sapindus mukorossi powder and extract with ethanol as the solvent for 3 hours. Filter to obtain the filtrate and residue. Perform Soxhlet extraction on the residue using an acetone-ethyl acetate mixture as the extraction solvent at 60℃-80℃ for 2 hours. After standing, filter to obtain the extract. Combine the filtered filtrate and the extracted extract, and remove the solvent by rotary evaporation to obtain a viscous paste, which is the Sapindus mukorossi extract. In the extract of Sapindus mukorossi, flavonoids can destroy the cell membrane of bacteria to achieve antibacterial effect; triterpenoid saponins can cause the hyphae in pathogens to twist and collapse, thin the cell wall, and greatly reduce the number of mitochondria in the bacteria, thereby depriving the bacteria of energy and thus killing them.

[0056] Paris polyphylla possesses excellent anti-tumor, antibacterial, and hemostatic effects. It exhibits certain inhibitory effects against acne-causing bacteria such as Propionibacterium acnes and Staphylococcus aureus, with a significantly lower risk of drug resistance compared to antibiotics. The extraction process for Paris polyphylla extract involves using whole herb powder as raw material, adding 3-30 parts by weight of 30%-100% ethanol, and refluxing three times at 0℃-90℃. The extracts are then combined, the ethanol is recovered under reduced pressure, and the solution is defatted with activated charcoal to obtain a wet extract, which is the Paris polyphylla extract. The main active ingredient in the Paris polyphylla extract is saponin, which possesses strong hemostatic and cytotoxic activity, and is beneficial for antibacterial and anti-inflammatory effects.

[0057] Purslane possesses excellent antibacterial, antioxidant, antitumor, and anti-inflammatory properties, exhibiting strong inhibitory effects against common bacteria and fungi, thus earning it the reputation of a "natural antibiotic." Its extract can improve facial skin inflammation and reduce erythema by lowering the levels of inflammatory factors in the serum of patients with facial glucocorticoid-dependent dermatitis, while also providing moisturizing benefits. The extraction process for purslane extract can utilize an acid-base method: Purslane leaves and stems are pulverized and soaked in water, then an appropriate amount of sulfuric acid is added to adjust the pH to approximately 2-3, facilitating the dissolution of flavonoids. Next, sodium hydroxide is used to adjust the pH to approximately 8-9, further facilitating the dissolution of saponins and alkaloids. Extraction is then performed using organic solvents such as ethanol or acetone to remove impurities, followed by concentration and drying to prepare the purslane extract. Purslane extract contains numerous compounds, among which flavonoids and polyphenols have broad-spectrum antibacterial properties and can inhibit bacteria by disrupting their cell membranes; coumarin compounds inhibit bacterial division and proliferation through their unique coumarin genes, thus achieving an antibacterial effect.

[0058] Extracts from Paris polyphylla, Sapindus mukorossi, and Portulaca oleracea all contain flavonoids and polyphenols. Flavonoids, which are present in all three, can further enhance the destruction of microbial cell membrane structure and the effect on microbial energy metabolism; while polyphenols have strong antioxidant effects, and phenolic substances also have a strong inhibitory effect on microorganisms.

[0059] Understandably, the compound of this application uses non-irritating bioactive surfactants and natural green plant extracts. Lipopeptides can effectively inhibit the catalytic conversion of androgens by 5α-reductase to a certain extent; glycolipids can treat rosacea and allergies, and inhibit Staphylococcus aureus; phospholipids can resist aging, enhance immunity, and inhibit inflammation; plant extracts can effectively and with low irritation inhibit acne-causing bacteria, and have antibacterial, anti-inflammatory, and soothing effects. The combined use of bioactive surfactants and plant extracts can quickly and effectively reduce excess sebum, reduce inflammation and swelling, and is safe and non-irritating.

[0060] In some embodiments, the lipopeptide biosurfactant includes one or more of subtilisin sodium, itursin, and lichenin.

[0061] In some embodiments, glycolipid biosurfactants include one or more of sophorolipids, rhamnolipids, and trehalolipids.

[0062] In some embodiments, phospholipid biosurfactants include one or more of lecithin, inositol phospholipids, and serine phospholipids.

[0063] As one possible implementation, the compound comprises, by weight parts: 2-30 parts of lipopeptide biosurfactants, 1-20 parts of glycolipid biosurfactants, 2-20 parts of phospholipid biosurfactants, 0.6-8 parts of Paris polyphylla extract, 1.2-10 parts of Sapindus mukorossi extract, 1.5-10 parts of Portulaca oleracea extract, 3-10 parts of nicotinamide, 2-5 parts of butylene glycol, and 0.14-1.34 parts of p-hydroxyacetophenone.

[0064] The weight percentage of lipopeptide biosurfactants in the compound is 2 to 30 parts; for example, it can be, but is not limited to, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, or any two of the above weight percentages.

[0065] The weight percentage of glycolipid biosurfactants in the compound is 1 to 20 parts; for example, it can be, but is not limited to, 1 part, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, or any two of the above weight percentages.

[0066] The weight percentage of phospholipid biosurfactants in the compound is 2 to 20 parts; for example, it can be, but is not limited to, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, or any two of the above weight percentages.

[0067] The weight parts of Paris polyphylla extract in the compound are 0.6 to 8 parts; for example, but not limited to 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, or any two of the above weight parts.

[0068] The weight parts of Sapindus mukorossi extract in the compound are 1.2 to 10 parts; for example, but not limited to 1.2 parts, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, or any two of the above weight parts.

[0069] The weight parts of purslane extract in the compound are 1.5 to 10 parts; for example, but not limited to 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, or any two of the above weight parts.

[0070] The weight parts of nicotinamide in the compound are 3 to 10 parts; for example, but not limited to 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts or any two of the above weight parts.

[0071] The weight parts of butanediol in the compound are 2 to 5 parts; for example, but not limited to 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, or any two of the above weight parts.

[0072] The weight parts of p-hydroxyphenylethanol in the compound are 0.14 to 1.34 parts; for example, but not limited to 0.14 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.34 parts, or any two of the above weight parts.

[0073] In the compound, when the weight proportions of lipopeptide biosurfactants, glycolipid biosurfactants, phospholipid biosurfactants, Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract are within the aforementioned ranges, they can effectively inhibit the catalytic conversion of androgens by 5α-reductase, improve acne, and also have antibacterial, anti-inflammatory, and soothing effects. Furthermore, niacinamide helps enhance the skin barrier function, improves skin hydration, and brightens the complexion; butylene glycol, as a solvent, provides moisturizing effects and also possesses certain antibacterial properties, i.e., it has a certain preservative effect.

[0074] As one possible implementation, the compound comprises, by weight, the following:

[0075] 2-30 parts of lipopeptide biosurfactants, 1-20 parts of glycolipid biosurfactants, 2-20 parts of phospholipid biosurfactants, 0.6-9 parts of Paris polyphylla extract, 1.2-14 parts of Sapindus mukorossi extract, 1.5-12 parts of Portulaca oleracea extract, 3-10 parts of nicotinamide, 2-5 parts of butylene glycol, and 0.14-1.34 parts of p-hydroxyacetophenone.

[0076] In some embodiments, the compound comprises, by weight:

[0077] 5-15 parts of lipopeptide biosurfactants, 2-8 parts of glycolipid biosurfactants, 3-7 parts of phospholipid biosurfactants, 2-6 parts of Paris polyphylla extract, 2-6 parts of Sapindus mukorossi extract, 2-6 parts of Portulaca oleracea extract, 5-8 parts of nicotinamide, 3-5 parts of butylene glycol, and 0.173-0.75 parts of p-hydroxyacetophenone.

[0078] As one possible implementation, the compound comprises, by weight, the following:

[0079] 10 parts of lipopeptide biosurfactants, 6 parts of glycolipid biosurfactants, 6 parts of phospholipid biosurfactants, 2 parts of Paris polyphylla extract, 2 parts of Sapindus mukorossi extract, 2 parts of Portulaca oleracea extract, 5 parts of nicotinamide, 3 parts of butylene glycol and 0.14 parts of p-hydroxyacetophenone.

[0080] In some embodiments, the compound also includes sodium hydroxide.

[0081] In some alternative embodiments, the amount of sodium hydroxide used is such that the pH of the compound is 6.8-7.2.

[0082] In some implementations, the compound also includes water.

[0083] As one possible implementation, the amount of water used is such that the total weight of the compound reaches 100 parts by weight.

[0084] It should be noted that the extracts of Paris polyphylla, Sapindus mukorossi, and Portulaca oleracea should all be prepared as aqueous solutions with a mass percentage concentration of 10%-40% before use.

[0085] As an example, an aqueous solution of Paris polyphylla extract can be prepared as follows: for every 100 parts of aqueous solution, deionized water is added and heated to dissolve 0.4 parts of p-hydroxyacetophenone preservative; after the solution is cooled to room temperature, 10-40 parts of powdered Paris polyphylla extract are uniformly stirred into the solution to prepare an aqueous solution of Paris polyphylla extract with a weight percentage of 10%-40%.

[0086] As an example, an aqueous solution of Sapindus mukorossi extract can be prepared as follows: for every 100 parts of aqueous solution prepared, deionized water is added and heated to dissolve 0.4 parts of p-hydroxyacetophenone preservative; after the solution is cooled to room temperature, 10-40 parts of powdered Sapindus mukorossi extract are uniformly stirred into the solution to prepare an aqueous solution of Sapindus mukorossi extract with a weight percentage of 10%-40%.

[0087] As an example, an aqueous solution of purslane extract can be prepared as follows: for every 100 parts of aqueous solution, deionized water is added and heated to dissolve 0.4 parts of p-hydroxyacetophenone preservative; after the solution is cooled to room temperature, 10-40 parts of powdered purslane extract are uniformly stirred into the solution to prepare an aqueous solution of purslane extract with a weight percentage of 10%-40%.

[0088] As an example, the compound of this application can be prepared as follows: When preparing 100 parts of the compound, take an appropriate amount of deionized water and heat it, add 0.14-1.34 parts of p-hydroxyacetophenone, and stir until it is evenly dissolved; then cool to room temperature, add 2-30 parts of lipopeptide biosurfactant and stir until it is dissolved, then add 2-20 parts of phospholipid biosurfactant and stir until it is dissolved; then add the following in the order of 1-20 parts of glycolipid biosurfactant, 2-5 parts of butylene glycol, 3-10 parts of nicotinamide, 0.6-8 parts of Paris polyphylla extract, 1.2-10 parts of Sapindus mukorossi extract, and 1.5-10 parts of Portulaca oleracea extract, and finally adjust the pH to about 7 with sodium hydroxide.

[0089] The second aspect of this application provides the use of the compound of the first aspect of this application in the preparation of one or more skin care cosmetics, detergent cosmetics, makeup products and shampoo and conditioner products.

[0090] A third aspect of this application provides a skin care product comprising a compound having acne-treating efficacy according to the first aspect of this application.

[0091] In some embodiments, the skin care product comprises, by weight, 0.1 to 5 parts of a compound, 0.2 to 0.8 parts of an antioxidant, 2 to 8 parts of an emulsifier, 10 to 20 parts of a moisturizer, 8 to 20 parts of a humectant, and 0.2 to 2 parts of a preservative.

[0092] In some embodiments, the skin care product comprises, by weight, 3-5 parts of a compound, 0.4-0.6 parts of an antioxidant, 3-5 parts of an emulsifier, 14-18 parts of a moisturizer, 8-12 parts of a humectant, and 0.4-1 part of a preservative.

[0093] In some embodiments, the skin care product also includes water.

[0094] In some alternative embodiments, the emulsifier in the skin care product includes one or more of the following: hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, cetearyl glucoside and cetearyl alcohol, eicosyl docosyl alcohol and eicosyl glucoside.

[0095] In some alternative implementations, the emollient in the skin care product includes one or more of isopropyl palmitate, isononyl isononanoate, and dioctyl carbonate.

[0096] In some alternative implementations, the moisturizer in the skin care product includes one or more of isohexadecane, butylene glycol, and glyceryl glucoside.

[0097] As one possible implementation, preservatives in skincare products include one or more of p-hydroxyacetophenone, capryloyl hydroxamic acid, and phenoxyethanol.

[0098] As an example, antioxidants include one or more of tocopheryl acetate, green tea extract, and sodium sulfite.

[0099] In some implementations, the skin care product is an emulsified skin cream.

[0100] Any suitable method within the technical field can be used to prepare emulsified skin creams.

[0101] The technical solutions of this application will be described in detail below with reference to specific embodiments. It should be understood that these embodiments are only for illustrating this application and are not intended to limit the scope of this application. For experimental methods in the following embodiments where specific conditions are not specified, please refer to the guidelines given in this application first, or follow experimental manuals or conventional conditions in the field, or follow the conditions recommended by the manufacturer, or refer to experimental methods known in the field.

[0102] In the specific embodiments described below, the measurement parameters involving raw material components may have slight deviations within the weighing accuracy range unless otherwise specified. Temperature and time parameters are subject to acceptable deviations due to instrument testing accuracy or operational precision.

[0103] It should be noted that the Paris polyphylla extract used in the following examples and comparative examples was purchased from Xi'an Xinlu Biotechnology Co., Ltd., and was a water-extracted dried pure powder with a content >99%; the Sapindus mukorossi extract was purchased from Xi'an Xinlu Biotechnology Co., Ltd., and was a water-extracted dried pure powder with a content >99%; the Portulaca oleracea extract was purchased from Xi'an Xinlu Biotechnology Co., Ltd., and was a water-extracted dried pure powder with a content >99%.

[0104] I. Preparation of compound with acne-treating effects

[0105] Example 1. Preparation of aqueous solutions of Paris polyphylla extract, Sapindus mukorossi extract and Portulaca oleracea extract

[0106] 1. Preparation of a 30% aqueous solution of Paris polyphylla extract

[0107] Weigh 69.6g of deionized water, add 0.4g of p-hydroxyacetophenone, and heat to dissolve the p-hydroxyacetophenone. After the solution cools to room temperature, add 30g of powdered Paris polyphylla extract evenly to the solution to prepare a 30% by weight aqueous solution of Paris polyphylla extract.

[0108] 2. Preparation of a 40% aqueous solution of Sapindus mukorossi extract

[0109] Weigh 59.6g of deionized water, add 0.4g of p-hydroxyacetophenone, and heat to dissolve the p-hydroxyacetophenone. After the solution cools to room temperature, add 40g of powdered Sapindus mukorossi extract evenly to the solution to prepare an aqueous solution of Sapindus mukorossi extract with a weight percentage of 40%.

[0110] 3. Preparation of a 30% aqueous solution of purslane extract

[0111] Weigh 69.6g of deionized water, add 0.4g of p-hydroxyacetophenone, and heat to dissolve the p-hydroxyacetophenone. After the solution cools to room temperature, add 30g of powdered purslane extract evenly to the solution to prepare an aqueous solution of purslane extract with a weight percentage of 30%.

[0112] Example 2. Preparation of Compound 1

[0113] Take 62.46g of deionized water and heat it. Add 0.1g of p-hydroxyacetophenone and stir until it dissolves. Then cool it to room temperature, add 10g of sodium subtilis lipopeptide and stir until it dissolves. Then add 6g of lecithin and stir until it dissolves. Then add the following ingredients in the following order: 6g of sophorolipid, 2g of butylene glycol, 3g of nicotinamide, 2g of 30% aqueous solution of Paris polyphylla extract, 3g of 40% aqueous solution of Sapindus mukorossi extract, and 5g of 30% aqueous solution of Portulaca oleracea extract. Stir and dissolve evenly. Finally, adjust the pH to about 7 with sodium hydroxide to obtain compound 1.

[0114] Examples 3-33. Preparation of Compounds 2-32

[0115] Compound 2-32 is similar to compound 1, the main difference being that the amount of at least one component is different, as detailed in Tables 1-1 and 1-2.

[0116] Comparative Example 1. Preparation of Compound D1

[0117] Compound D1 is similar to compound 1, the main difference being that the amount of at least one component is different, as detailed in Table 1-2.

[0118] Table 1-1

[0119]

[0120] Table 1-2

[0121]

[0122] II. Antibacterial and soothing efficacy tests of compound formulations with acne-treating effects

[0123] The compound preparations obtained in the above embodiments were subjected to antibacterial and soothing effect tests, and the test methods are as follows:

[0124] 1. Malassezia inhibition rate experiment

[0125] The shaking flask method was used.

[0126] Experimental Methods: The acne-reducing and soothing compound, bacterial suspension, and PBS buffer were added to an Erlenmeyer flask to achieve a compound concentration of 80 μmol / L. One loopful of Malassezia bacterial colony was picked to maintain a bacterial suspension concentration of 1×10⁻⁶ in PBS. 4 cfu / mL -5×10 4 cfu / mL. Fix the Erlenmeyer flask containing the bacterial suspension to a shaking incubator and shake at 300 r / min for 2 min at 20℃-25℃. Take out 1 mL, filter it with a sterile filter membrane, wash it 3 times with PBS, remove the filter membrane, place it in a petri dish, wash off the test bacteria on the filter membrane with PBS, and dilute it appropriately to 10 cfu / mL-2 cfu / mL as the test group sample solution before shaking.

[0127] The Erlenmeyer flask containing the bacterial suspension of the compound was fixed in a shaking incubator and shaken for 1 h under the same conditions and shaking method. 1 mL of the solution was filtered to remove the test powder and appropriately diluted to obtain the post-shaking test group sample. 1 mL of both the pre-shaking and post-shaking sample solutions were inoculated into two Petri dishes using the agar pour method, and viable cell counts were performed before and after shaking. A negative control group was prepared without adding the test sample and without filtration, following the same procedures as the test group. The viable cell count in the control group without the sample was controlled at 1 × 10⁻⁶. 4 cfu / mL -5×10 4 The cfu / mL count was determined by counting viable bacteria before and after shaking. The experiment was repeated three times, and the average value was calculated.

[0128] Antibacterial rate (η) = ,

[0129] In the formula: B is the average colony count before sample shaking; A is the average colony count after sample shaking.

[0130] 2. Antibacterial rate experiment of Propionibacterium acnes

[0131] The shaking flask method was used.

[0132] Experimental Methods: The acne-reducing and soothing compound, bacterial suspension, and PBS buffer were added to an Erlenmeyer flask to achieve a compound concentration of 80 μmol / L. A loopful of Propionibacterium acnes bacterial colony was picked, and the bacterial suspension was controlled at a concentration of 1×10⁻⁶ in PBS. 4 cfu / mL -5×10 4 CFU / mL. Fix the Erlenmeyer flask containing the bacterial suspension to a shaking incubator and shake at 300 r / min for 2 min at 20 ℃~25 ℃. Take out 1 mL, filter it with a sterile filter membrane, wash it 3 times with PBS, remove the filter membrane, place it in a petri dish, wash off the test bacteria on the filter membrane with PBS, and dilute it appropriately to 10 CFU / mL - 2 CFU / mL as the test group sample solution before shaking.

[0133] The Erlenmeyer flask containing the bacterial suspension of the compound was fixed in a shaking incubator and shaken for 1 h under the same conditions and shaking method. 1 mL of the solution was filtered to remove the test powder and appropriately diluted to obtain the post-shaking test group sample. 1 mL of both the pre-shaking and post-shaking sample solutions were inoculated into two Petri dishes using the agar pour method, and viable cell counts were performed before and after shaking. A negative control group was prepared without adding the test sample and without filtration, following the same procedures as the test group. The viable cell count in the control group without the sample was controlled at 1 × 10⁻⁶. 4 cfu / mL 5×10 4 The cfu / mL count was determined by counting viable bacteria before and after shaking. The experiment was repeated three times, and the average value was calculated.

[0134] Antibacterial rate (η) = ,

[0135] In the formula: B is the average colony count before sample shaking; A is the average colony count after sample shaking.

[0136] 3. Soothing effect test

[0137] The soothing effect was tested using a lactic acid stinging test.

[0138] (1) The experimental mechanism is: when the skin barrier is damaged, lactic acid enters the skin and stimulates unmyelinated C-type nerves, thereby producing a stinging sensation.

[0139] (2) Test method: Under constant temperature and humidity, 50 μL of 10% lactic acid solution was applied to the nasolabial fold and one cheek. Subjects were asked about their subjective symptoms at 2.5 min and 5 min, and scored on a 4-point scale (0 points for no stinging sensation, 1 point for mild stinging sensation, 2 points for moderate stinging sensation, and 3 points for severe stinging sensation). The two scores were added together, and a total score of ≥3 points was considered a positive lactic acid stinging reaction.

[0140] (3) Testing process: The lactic acid stinging test requires the use of a soothing sample twice a day for 28 consecutive days (i.e., four weeks). Testing and evaluation are conducted on D0, D14, and D28. If the lactic acid stinging score decreases significantly after 28 days of using the test product compared to before use, it indicates that the skin's reactivity to external stimuli is reduced, meaning the product has a repairing effect.

[0141] The test results are shown in Table 2.

[0142] Table 2

[0143]

[0144] The results of compound 27-32 show that no plant extracts were added, and the compound was prepared using only lipopeptide biosurfactants, glycolipid biosurfactants, or phospholipid biosurfactants, which have antibacterial and soothing effects.

[0145] The comparison of the results of compound 12-23 and compound D1 shows that, compared with the addition of no biosurfactants, the use of lipopeptide biosurfactants, glycolipid biosurfactants or phospholipid biosurfactants to prepare compound products can improve the antibacterial and soothing effects of the compound products.

[0146] The comparison of the results of compound 1 and compounds 12-23 shows that, compared with using only lipopeptide biosurfactants, glycolipid biosurfactants, or phospholipid biosurfactants, the simultaneous use of lipopeptide biosurfactants, glycolipid biosurfactants, and phospholipid biosurfactants in the preparation of the compound can further improve the antibacterial and soothing effects of the compound; indicating that the combined use of lipopeptide biosurfactants, glycolipid biosurfactants, and phospholipid biosurfactants has a synergistic effect.

[0147] The results of compound 1-32 show that compound 3 has the best antibacterial and soothing effects.

[0148] A comparison of the results of compounds 12-23, 27-32, and D1 shows that the simultaneous use of bioactive surfactants and plant extracts in the preparation of compounds can improve their antibacterial and soothing effects. This indicates that the combined use of bioactive surfactants and plant extracts has a synergistic effect.

[0149] Comparing the results of compound 3 with those of compounds 4-6, it can be seen that, compared with using only Paris polyphylla extract, Sapindus mukorossi extract or Portulaca oleracea extract, using Paris polyphylla extract, Sapindus mukorossi extract and Portulaca oleracea extract can further improve the antibacterial and soothing effects of the compound; indicating that using Paris polyphylla extract, Sapindus mukorossi extract and Portulaca oleracea extract together has a synergistic effect.

[0150] III. Safety Testing of Ingredients in Compounds with Acne Treatment Effects

[0151] The components used in the compound were subjected to acute dermal toxicity tests, acute skin irritation tests, acute eye irritation tests, and skin sensitization tests. The specific experimental methods are as follows:

[0152] 1. Acute percutaneous toxicity test

[0153] The toxicity of the tested sample shall be determined in accordance with the requirements of the "Guidelines for Chemical Testing" (HJ / T153-2004) and "Methods for Chemical Testing (Health Effects)" 402: Acute Dermal Toxicity Test (Chemical Registration Center of the Ministry of Environmental Protection, 2013).

[0154] 2. Acute skin irritation test

[0155] The skin irritation of the tested samples is determined in accordance with the "Guidelines for Chemical Testing" (HJ / T 153-2004) and the "Test Methods for Acute Skin Irritation / Corrosion of Chemicals" (GB / T 21604-2008).

[0156] 3. Acute eye irritation test

[0157] The eye irritation of the tested samples is determined in accordance with the "Guidelines for Chemical Testing" (HJ / T 153-2004) and the "Test Methods for Acute Eye Irritation / Corrosion of Chemicals" (GB / T 21609-2008).

[0158] 4. Skin sensitization test

[0159] Skin sensitization tests were conducted using the Buehler test.

[0160] The sensitization of the tested sample is determined according to the "Guidelines for Cosmetic Testing" (HJ / T 153-2004) and the "Cosmetic Testing Methods: Health Effects Volume"-406: Skin Sensitization Test (Chemical Registration Center of the Ministry of Environmental Protection, 2013) Magnusson classification standard for sensitization intensity.

[0161] The experimental results are shown in Table 3.

[0162] Table 3

[0163]

[0164] As shown in Table 3, the ingredients used in the compound with acne-treating effects provided in this application are safe, with no skin toxicity, irritation, or sensitization, and no eye irritation.

[0165] IV. Preparation of skincare products with acne-treating effects

[0166] Application Example 1

[0167] Mix 5g of compound 3 prepared in Example 4, 0.5g of tocopheryl acetate, 3.5g of cetearyl glucoside and cetearyl alcohol (as emulsifier), 16g of isopropyl palmitate (as emollient), 10g of isohexadecane (as moisturizer), 0.2g of p-hydroxyacetophenone (as preservative) and 0.4g of capryloyl hydroxamic acid (as preservative), and then add water to 100g to prepare a skin cream with acne treatment efficacy.

[0168] Comparative Application Example 1

[0169] The difference between Application Example 1 and Application Example 2 is that Compound 3 was not added, and an equal amount of water was used to replace Compound 3; the details are as follows:

[0170] Mix 0.5g tocopheryl acetate, 3.5g cetearyl glucoside and cetearyl alcohol (as emulsifier), 16g isopropyl palmitate (as emollient), 10g isohexadecane (as moisturizer), 0.2g p-hydroxyacetophenone (as preservative) and 0.4g capryloyl hydroxamic acid (as preservative), then add water to 100g to prepare a skin cream with acne-treating effects.

[0171] V. Efficacy Testing of Skin Care Creams with Acne Treatment Effects

[0172] Twenty qualified volunteers were recruited to test the efficacy of a skincare cream in treating acne and its soothing effects. The specific testing method was as follows: volunteers applied the cream sample prepared in Application Example 1 (referred to as Sample 1) and the control cream sample prepared in Application Example 1 (referred to as Sample 2) to the left and right halves of their faces, respectively. The cream was applied twice daily after cleansing the face for two consecutive weeks. The degree of lesion regression after simultaneous application of Samples 1 and 2 was compared. Three volunteers were randomly selected, and the results are shown in Table 4.

[0173] Table 4

[0174]

[0175] As shown in Table 4, the skin cream containing compound ingredients that have the effect of treating acne has an inhibitory effect on Malassezia and Propionibacterium acnes, and also has a certain soothing effect, which can effectively treat acne and reduce inflammation and swelling.

[0176] In summary, the compound provided in this application, composed primarily of bioactive surfactants, Paris polyphylla extract, Sapindus mukorossi extract, and Portulaca oleracea extract, exhibits excellent inhibition rates against acne-causing bacteria such as Propionibacterium acnes. This compound can also be used in skincare products, demonstrating good product stability and combining acne-treating and soothing effects.

[0177] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0178] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A compound with therapeutic effects on acne, characterized in that, The compound comprises, by weight parts: The composition includes 2-30 parts of lipopeptide biosurfactant, 1-20 parts of glycolipid biosurfactant, 2-20 parts of phospholipid biosurfactant, 0.6-8 parts of Paris polyphylla extract, 1.2-10 parts of Sapindus mukorossi extract, 1.5-10 parts of Portulaca oleracea extract, 3-10 parts of nicotinamide, 2-5 parts of butylene glycol, and 0.14-1.34 parts of p-hydroxyacetophenone; wherein the lipopeptide biosurfactant is sodium subtilis lipopeptide, the glycolipid biosurfactant is sophorolipid, and the phospholipid biosurfactant is lecithin.

2. The compound as described in claim 1, characterized in that, The compound comprises, by weight parts: 5-15 parts of lipopeptide biosurfactants, 2-8 parts of glycolipid biosurfactants, 3-7 parts of phospholipid biosurfactants, 2-6 parts of Paris polyphylla extract, 2-6 parts of Sapindus mukorossi extract, 2-6 parts of Portulaca oleracea extract, 5-8 parts of nicotinamide, 3-5 parts of butylene glycol, and 0.173-0.75 parts of p-hydroxyacetophenone.

3. The compound as described in claim 1, characterized in that, The compound comprises, by weight parts: 10 parts of lipopeptide biosurfactants, 6 parts of glycolipid biosurfactants, 6 parts of phospholipid biosurfactants, 2 parts of Paris polyphylla extract, 2 parts of Sapindus mukorossi extract, 2 parts of Portulaca oleracea extract, 5 parts of nicotinamide, 3 parts of butylene glycol and 0.14 parts of p-hydroxyacetophenone.

4. The compound as described in claim 1, characterized in that, The compound also includes sodium hydroxide.

5. The compound as described in claim 4, characterized in that, The amount of sodium hydroxide used is such that the pH of the compound is 6.8-7.

5.

6. The compound as described in claim 1, characterized in that, The compound also includes water.

7. The compound as described in claim 6, characterized in that, The amount of water used, by weight, makes the total weight of the compound reach 100 parts.

8. The use of the compound having acne-treating efficacy as described in any one of claims 1 to 7 in the preparation of one or more skin care cosmetics, cleansing cosmetics, and makeup products.

9. The application as described in claim 8, characterized in that, The aforementioned cleansing cosmetics include shampoo and conditioner products.

10. A skincare product, characterized in that, Includes the compound having acne-treating efficacy as described in any one of claims 1 to 7.

11. The skincare product as described in claim 10, characterized in that, The skincare products comprise, by weight, the following: 0.1 to 5 parts of the compound, 0.2 to 0.8 parts of an antioxidant, 2 to 8 parts of an emulsifier, 10 to 20 parts of a skin emulsifier, 8 to 20 parts of a moisturizer, and 0.2 to 2 parts of a preservative.

12. The skincare product as described in claim 11, characterized in that, The skincare products comprise, by weight, the following: The compound contains 3-5 parts of the compound, 0.4-0.6 parts of an antioxidant, 3-5 parts of an emulsifier, 14-18 parts of a skin emulsifier, 8-12 parts of a moisturizer, and 0.4-1 part of a preservative.

13. The skincare product according to any one of claims 11 to 12, characterized in that, The skin care product includes at least one of the following features (1)-(5): (1) The emulsifier includes one or more of the following: hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, cetearyl glucoside and cetearyl alcohol, eicosyl docosyl alcohol and eicosyl glucoside; (2) The emollients include one or more of isopropyl palmitate, isononyl isononyl isononyl carbonate and dioctyl carbonate; (3) The moisturizer includes one or more of isohexadecane, butanediol and glyceryl glucoside; (4) The preservatives include one or more of p-hydroxyacetophenone, octanoyl hydroxamic acid and phenoxyethanol; (5) The antioxidants include one or more of tocopheryl acetate, green tea extract and sodium sulfite.

14. The skincare product according to any one of claims 11 to 12, characterized in that, The skincare product in question is an emulsified skincare cream.

Images